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Abstract
Background
Serological assays to determine HIV incidence have contributed to estimates of HIV inci-
dence, monitoring of HIV spread, and evaluation of prevention strategies. Two frequently
used incidence assays are the Sedia HIV-1 LAg-Avidity EIA (LAg) and the Bio-Rad avidity
incidence (BRAI) assays with a mean duration of recent infection (MDRI) of 130 and 240
days for subtype B infections, respectively. Little is known about how these assays perform
with recombinant HIV-1 strains. We evaluated the concordance of these assays in a popula-
tion infected mainly with HIV-1 CRF06_cpx.
Material/Methods
Remnant serum samples (n = 288) collected from confirmed, newly-diagnosed HIV-positive
persons from Estonia in 2013 were tested. Demographic and clinical data were extracted
from clinical databases. LAg was performed according to the manufacturer’s protocol and
BRAI testing was done using a validated protocol. Samples with LAg-pending or BRAI-
invalid results were reclassified as recent if they were from persons with viral loads <1000
copies/mL or were reclassified as long-term if presenting with AIDS.
Results
In total 325 new HIV infections were diagnosed in 2013 in Estonia. Of those 276 persons
were tested with both LAg and BRAI. Using assay results only, the recency rate was 44%
and 70% by LAg and BRAI, respectively. The majority of samples (92%) recent by LAg were
recent by BRAI. Similarly, 89% of samples long-term by BRAI were long-term by LAg. After
clinical information was included in the analysis, the recency rate was 44% and 62% for LAg
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and BRAI, respectively. The majority of samples (86%) recent by LAg were recent by BRAI
and 91% of long-term infections by BRAI were long-term by LAg.
Conclusions
Comparison of LAg and BRAI results in this mostly CRF06_cpx-infected population showed
good concordance for incidence classification. Our finding of a higher recency rate with
BRAI in this population is likely related to the longer MDRI for this assay.
Introduction
Estonia has the highest prevalence of HIV infections in the European Union. The HIV epi-
demic in Estonia likely started in 2000 among people who inject drugs (PWID) with infections
mainly caused by circulating recombinant form CRF06_cpx [1, 2]. Despite a decline in the
number of individuals newly diagnosed with HIV, from a total of 1,474 in 2001 to 229 in 2016,
the rate of newly diagnosed infections is still high (approximately 17 per 100,000 persons in
2016) (Estonian Health Board; www.terviseamet.ee). In this situation, and outbreaks in gen-
eral, the detection of recent HIV infection is important for describing the epidemic, monitor-
ing spread, and developing and implementing important public health service interventions
that prevent further HIV transmission. Thus, having a reliable incidence assay is essential for
finding newly infected individuals and for assessing the efficacy of public health interventions.
Over the years, many different incidence assays have been developed. Assays are based on
antibody titer [3, 4], avidity [5, 6], the proportion of HIV-1-specific immunoglobulin G (IgG)
antibodies relative to total IgG [7] in human plasma and/or serum samples or a combination
of these biomarkers [8, 9]. Previously, the BED-capture-enzyme immunoassay was the most
commonly used assay globally [7]; however, its over-estimation of recent infections led to the
development of new assays. This incidence test was called BED since it included HIV envelope
antigens to subtypes B, E, and D. Now, two avidity-based assays with improved accuracy are in
use–Sedia TM HIV-1 LAg Avidity EIA (LAg) [6, 10] and the Bio-Rad avidity incidence assay
(BRAI), which was developed by scientists at the US Centers for Disease Control and Preven-
tion (CDC) [11–13]. Both assays measure the binding strength (or avidity) of HIV antibodies
to viral proteins, which is known to be lower in early stages of infection and increases while
infection is progressing. LAg uses a multi-subtype (B, E, and D) gp41 recombinant envelope
protein and BRAI uses a broader spectrum of proteins from HIV-1 Group M (subtype B) and
Group O, and HIV-2 since it is a modification of an existing commercial assay for detecting
HIV antibodies (Genetics Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad Laboratories). In both
assays, the use of a chaotropic agent is included so that less avid antibodies are dissociated and
washed away, leaving only the strongly bound antibodies to be detected in the assays [6, 10–
12].
Incidence assays can misclassify HIV-1-infected persons as having recent infection in indi-
viduals who have received antiretroviral therapy (ART) for long periods with viral suppression,
elite controllers and persons with AIDS [13–15]. In addition, studies have shown that the per-
formance of recency assays depends on the HIV-1 subtype, such that the mean duration of
recent infection (MDRI) differs between subtypes. MDRI is a characteristic of recency assays
defined as the average time spent ‘recently’ infected. For the LAg assay, the MDRI is 130 days
for subtype B, 161 days for subtype A, 211 days for subtype A1, 273 days for subtype D, and
one study has determined 109 days for combined samples of subtypes A and D with the
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normalized optical density (ODn) cut-off 1.5 [14, 16, 17]. The CDC calculated MDRI for BRAI
is 240 days for subtype B using an avidity index (AI) cut-off of 30% [12, 18]. According to an
evaluation by the Consortium for the Evaluation and Performance of HIV Incidence Assays,
for an AI cut-off of 40%, the BRAI MDRI is the same for subtype B and C, 299 and 298 days,
respectively, but longer for subtypes D and A1, 467 and 364 days, respectively [14].
Performance evaluation of incidence assays has been limited to a few non-recombinant and
recombinant HIV-1 subtypes. We thus aimed to compare the performance of two frequently
used HIV-1 recency assays, LAg and BRAI, in a population mostly infected with CRF06_cpx
viruses. Since the LAg MDRI is shorter than that for BRAI (for subtypes for which MDRIs
have been calculated), we hypothesised that if the discrepancy between the assays is solely due
to differences in MDRIs then; (i) BRAI would have a higher recent infection rate than LAg; (ii)
most recent infections by LAg would be recent by BRAI, and (iii) most long-term infections by
BRAI would also be long-term by LAg.
Material and methods
Samples and demographic and clinical data
Remnant serum samples from individuals with newly-diagnosed HIV infection in Estonia
between January and December 2013 were collected by the Estonian HIV Reference Labora-
tory. All samples were positive for HIV-1 by ELISA (HIV Ag/Ab Combo Assay; Abbott Labo-
ratories Diagnostics Division, IL, USA or HIV Combi PT; Roche Diagnostics GmbH,
Mannheim, Germany) and confirmed by Western blot (WB; NEW LAV BLOT I and NEW
LAV BLOT II, Bio-Rad Laboratories Inc, Hercules, California, USA) or if WB-negative by
HIV Ag and HIV Ag Confirmatory testing (both Roche Diagnostics GmbH, Mannheim, Ger-
many) in the Estonian HIV Reference Laboratory. Serum was aliquoted and stored at -80˚C
until further analysis up to a maximum of two years. All study subjects were ART-naïve at the
time of sampling. There were 325 newly diagnosed HIV-positive persons during the study
period; 288 serum samples (88.6%) were available for LAg testing and 276 (85%) for BRAI test-
ing. Further analyses were performed on the population that had results for both LAg and
BRAI assays (N = 276). The study was approved by the Research Ethics Committee of the Uni-
versity of Tartu.
Demographic data (gender, age, date of diagnosis, and reason for testing) of study partici-
pants were extracted from the Estonian Health Board clinical database (Table 1). In addition,
the possible date of infection, self-reported HIV transmission route, concomitant AIDS defin-
ing condition(s), HIV-1 viral load (VL), HCV serostatus, and CD4+ T cell count within six
months of diagnosis were obtained from the Estonia HIV database [19]. In order to identify
the last negative HIV-1 antibody test within two years prior to HIV diagnosis, the laboratory
databases of four main hospitals (Tartu University Clinics, West-Tallinn Central Hospital,
Narva Hospital, and Ida-Viru Central Hospital) were searched in April 2015. In addition, the
date and HIV-1 VL measurements within six months of diagnosis for persons not in the Esto-
nia-HIV database were requested from hospital laboratory databases.
HIV subtype determination
HIV-1 subtypes were determined as follows. HIV-1 pol region sequences of PR codons 24–99
and RT codons 1–235 from study subjects (GenBank accession numbers MK793369—
MK793577) with subtype reference sequences from the Los Alamos HIV Sequence Database
[accession numbers AF004885 (subtype A1), DQ676872 (A1), AF286238 (A2), K03455 (B),
U52953 (C), K03454 (D), AF077336 (F1), AY371158 (F2), AF084936 (G), AF190127 (H),
EF614151 (J), AJ249235 (K), U54771 (CRF01_AE), AY271690 (CRF02_AG), AF414006
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(CRF03_AB), AB286851 (CRF06_cpx), AJ245481 (CRF06_cpx), and AF064699 (CRF06_cpx)]
and recent sequences from Estonia and Russia [AY500393 (A1), AY535659 (CRF06_cpx), and
DQ400856 (CRF06_cpx)] (www.hiv.lanl.gov) were used for using phylogenetic analysis
(MEGA 5). The tree was rooted by the HIV-1 group O sequence (L20587). The maximum like-
lihood (ML) phylogenetic tree was constructed with default values (substitution model:
Tamura- Nei; bootstrap replications: 500).
Incidence assays
Serum samples were first tested using the LAg assay (Sedia HIV-1 LAg Avidity EIA; Sedia Bio-
sciences Corporation, Portland, OR, USA) according to the manufacturer’s protocol. Briefly,
0.1 M citrate buffer was used as a dissociation agent and the avidity value [normalized optical
density (ODn)] was calculated by dividing the OD of sample, control, or calibrator with the
median OD of the calibrator. After a first round of testing, samples with ODn value of> 2.0
were classified as long-term infection and samples with an ODn� 2.0 were retested in tripli-
cate. The retested samples with a median ODn� 1.5 for the triplicate results were classified as
recent infections and those > 1.5 as long-term infections (Fig 1A). Specimens with an
ODn< 0.4 were considered “pending” until HIV seroreactivity was confirmed, in which case
they were classified as recent if determined to HIV detectable HIV antibody.
The BRAI assay was performed according to the CDC developed protocol using the com-
mercial Genetics Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad Laboratories Inc., CA, USA)
[12, 14] (Fig 1B). All samples were diluted 1:10 in a cold specimen diluent, transferred into two
Table 1. Characteristics of the Estonian study population tested by the incidence assays.
Variables Study population
N = 276
Male 170 (61.1%)
Median age (years) 32 (IQR: 28–41.5)
Route of transmission
Sexual 154 (55.8%)
Parenteral 59 (21.4%)
Perinatal 1 (0.4%)
Unknown 62 (22.4%)
Median VL (log10 copies/ml) 4.9 (IQR: 4.4–5.6)
Median CD4+ T cells count (cells/μl) 359.5 (IQR: 205–524)
Person presenting with AIDS 13 (4.7%)
Persons with time of possible infection reported 5 (1.8%)
HCV serostatus
Negative
Positive
Unknown
89 (32.3%)
79 (28.6%)
108 (39.1%)
HIV-1 subtypes
CRF06_cpx
A1
B
CRF06A1
C
Not determined�
172 (62.3%)
23 (8.3%)
7 (2.5%)
6 (2.2%)
1 (0.4%)
67 (24.3%)
�PCR or sequencing of the samples was unsuccessful; CRF, circulating recombinant form; CRF06A1, recombinant
form between CRF06_cpx and A1; IQR, interquartile range; VL, viral load.
https://doi.org/10.1371/journal.pone.0217048.t001
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Fig 1. Testing algorithms for determination of recent (R) and long-term (LT) HIV-1 infections by the (a) LAg and (b)
BRAI avidity assays. Dashed arrows in the algorithms indicate that all specimens classified as LAg-pending were
reclassified as R because all samples were collected from persons confirmed to be HIV-positive and all BRAI-invalid results
were reclassified as R because all samples were collected from individuals who were confirmed to have HIV infection, were
treatment naïve and not classified as having AIDS. �BRAI cut-off is the mean of the optical density of the assay negative
controls plus 0.250. ODn, normalized optical density.
https://doi.org/10.1371/journal.pone.0217048.g001
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wells of the antigen- coated plate and incubated for one hour at 4˚C. Next, either 0.1M diethy-
lamine (DEA), a dissociation agent, or 1x wash buffer was added to separate specimen wells.
After a 30 min incubation at 37˚ C, testing was performed as indicated in manufacture’s proto-
col. One each previously characterized recent and long-term serum controls were used in each
plate to validate each assay run. The test plate was considered valid if (i) the recent control was
below 20%, (ii) the (long-term) prevalent control was higher than 80% and (iii) both indexes
were within 2 standard deviations of the mean of 20 previous runs. The optical density (OD)
of the well treated with 1X wash buffer must be higher than the run cut-off (mean of OD of
negative controls plus 0.250) to calculate an avidity index (AI) using the following formula:
OD (DEA)/OD (wash buffer) x 100. If the OD of the well treated with 1X wash buffer was
lower than the cut-off value, then the sample was considered “invalid”. Samples with an AI
between 20% and 50% were retested in duplicate and the final AI is calculated as the mean of
the duplicates. Samples with a final AI� 30% were determined to be recent (Fig 1B). All BRAI
invalid results were reclassified as recent infections if samples were collected from persons
confirmed to have HIV infection, were treatment naïve (VL> 1000 copies/ml) and were not
classified as having AIDS (based on the presence of opportunistic infections at the time of HIV
diagnosis).
For both assays, samples with an HIV-1 VL<1000 copies/mL and those from persons pre-
senting with AIDS were reclassified as long-term infection [13–15].
Results
Recency rates and assay concordance
Avidity assay results were first analysed without considering the clinical data in order to evalu-
ate the direct concordance between both assays. We compared assays using 276 samples that
had results of the both assays (Fig 2). Table 1 describes the demographic and clinical character-
istics of the samples tested by the assays. After reclassifying specimens with LAg-pending and
BRAI-invalid results with confirmed HIV infection by WB or Ag testing (see methods) as
recent infections, the recency rates were 43% (119/276; 95% confidence interval [CI] 37–49%)
and 70% (192/276; 95% CI 64–75%) by LAg and BRAI, respectively. The Cohen’s kappa of
comparison of the assays was 0.37 (95% CI 0.28–0.47). Most LAg recent results were recent by
BRAI; of 119 LAg recent, 110 were BRAI recent (92%; 95% CI 86–96%). Most samples with
BRAI long-term results (84) were long-term by LAg (75) (89%; 95% CI 80–95%).
Next, in order to evaluate the use of a testing algorithm for determining recency estimates,
we analysed the results of samples with reported HIV-1 VL results within six months of
recency testing. When taking into account HIV-1 VL and the presence of AIDS, the recency
rate was similar for LAg but slightly lower for BRAI (Fig 3). There were 85 of 197 subjects
(43%; 95% CI 36–50%) classified as recent infection by LAg (Fig 3). Five persons with VL
<1000 copies/mL and another two presenting with AIDS were reclassified as long-term infec-
tions. For BRAI there were 122 of 197 persons (62%; 95% CI 55–69%) determined as recent
infection; eight had a VL<1000 copies/mL and another six presented with AIDS and were all
reclassified as long-term infections (Fig 3).
Avidity results after inclusion of clinical data were similar to those observed without inclu-
sion of the clinical data (Figs 2 and 3). Not all LAg recent results were recent by BRAI. We
found that 92% (78/85%; 95% CI 83–96%) of LAg-recent samples were recent by BRAI. Simi-
larly, not all BRAI-long-term results were long-term by LAg; 91% (68/75; 95% CI 81–96%) of
BRAI-long-term samples were long-term by LAg. An evaluation of the LAg and BRAI results
among persons infected with CRF06_cpx showed that 91% (57/63; 95% CI 80–96%) of samples
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were recent by both assays and 83% (29/35; 95% CI 66–93%) of samples were long-term by
both assays.
Next, we compared demographic and clinical characteristics between persons with recent
and long-term infections in both assays separately (Table 2). We observed that persons who
were LAg-recent had a higher prevalence of HCV seropositivity than those determined to be
LAg- long-term. More persons with BRAI-long-term results were male compared to the
BRAI-recent group. The recently infected group according to BRAI had higher CD4+ T cell
counts compared to the long-term infected group (383 vs 295 cells/μL; p = 0.01) which was not
observed for LAg. In both assays, among recently infected persons, the CRF06_cpx genotype
was more prevalent than in persons with established infection. Other variables did not differ
between the recent and long-term infection groups with either assay.
Specimens with pending and invalid results
In total, 48 samples (17%) were initially classified as pending (ODn < 0.4) by LAg and were
reclassified as recent following confirmation of infection by detection of HIV antibodies or
antigen. Of them, 34 (71%) had HIV-1 VL results within six months of HIV diagnosis. For
BRAI, 18 samples (9%) had invalid results, including 14 (78%) with HIV-1 VL results within
Fig 2. Determination of recent (R) and long-term (LT) HIV-1 infections by LAg and BRAI without inclusion of clinical data in the analysis.
https://doi.org/10.1371/journal.pone.0217048.g002
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six months of HIV diagnosis. Of the 34 LAg-pending and 14 BRAI-invalid specimens, 31 and 12
had CD4+ T cell count measurements, respectively. Both, LAg-pending and BRAI-invalid sam-
ples had high CD4+ T cell counts with medians of 506 cells/μL (IQR 363–656 cells/μL) and 596
cells/μL (IQR 340–935 cells/μL), respectively. As shown in Fig 4, there was a difference in the
median CD4+ T cell counts between the pending/invalid and long-term groups. In addition, with
BRAI there was a significant difference between the invalid and recent groups. The LAg-pending
group did not differ by HIV-1 VL compared to the LAg recent and LAg long-term groups (5.1
[IQR 4.6–6.4] log10 copies/ml vs 4.9 [IQR 4.2–5.7] log10 copies/ml and 5.0 [IQR 4.5–5.5] log10
copies/ml, respectively; both p>0.05). The BRAI-invalid group had higher HIV-1 VLs compared
to the BRAI-recent and BRAI-long-term groups (6.2 [IQR 5.5–7.0] log10 copies/ml vs 4.9 [IQR
4.3–5.5] log10 copies/ml and 5.2 [IQR 4.5–5.7] log10 copies/ml, respectively; both p>0.05).
Assay performance of samples with a reported possible infection date
Four subjects reported a possible infection date; all five persons were assumed to be infected
within 111 days before HIV diagnosis (median of 74 days [IQR 69–87]) and determined to be
recent infections by both assays.
Fig 3. Reclassification of recent (R) and long-term (LT) infections by LAg and BRAI after including clinical data into the testing algorithm. �R by LAg
includes 34 LAg-pending; ��R by BRAI includes 14 BRAI-invalid samples with available viral load (VL) results performed within six months of serum
collection.
https://doi.org/10.1371/journal.pone.0217048.g003
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Overall, previous HIV test data were available for 39/276(14%) participants; none had a
prior negative test within the last 130 days, seven had negative results within 240 days and 27
(including the previous seven) had negative test results within the last two years. The distribu-
tion of these subjects according to LAg and BRAI assay final results are provided in Table 3. In
total, 16/19 persons (84%) were determined as recent by both assays. Finally, we estimated the
duration of infection as the midpoint between last negative and first HIV positive test and cor-
related these results with the avidity as measured by ODn and AI. We found no correlation
between the estimated duration of infection and avidity (r = 0.31 and r = 0.30, respectively; for
both p> 0.05).
Discussion
We report the first study describing the performance evaluation of two avidity assays, LAg and
BRAI, for determining incidence in a large number of patients from Estonia infected with
HIV-1 recombinant form CRF06_cpx and URFs. Overall, we found high concordance
between both assays for determining recency. However, not all specimens with LAg recent
results were recent by BRAI and not all specimens with BRAI-long-term results were long-
term by LAg, which is likely explained by the different MDRIs of each assay, with the longer
MDRI for BRAI likely identifying more recent infections than the LAg assay. Using a high
CD4+ T cell count as a proxy for recent infection, our results suggest that BRAI may distin-
guish recent and long-term infection to a greater extent than LAg in the Estonian population.
Table 2. Demographic and clinical data of persons with HIV-1 viral loads measured within 6 months after HIV diagnosis classified as long-term or recent by LAg
and BRAI.
LAg
N = 197
BRAI
N = 197
Long-term
N = 112
Recent
N = 85
p Long-term
N = 75
Recent
N = 122
p
Male 68 (61%) 47 (56%) 0.47 53 (70%) 62 (51%) 0.01
Median age (years) 34
(IQR: 29–41)
31
(IQR: 26–41)
0.06 33
(IQR: 28–42)
32
(IQR: 26–41)
0.13
Route of transmission
Sexual 68 (61%) 47 (55%) 0.31 39 (52%) 76 (62%) 0.38
Parenteral 25 (22%) 25 (30%) 21 (28%) 29 (24%)
Unknown 19 (17%) 13 (15%) 15 (20%) 17 (14%)
Median VL (log10 copies/ml) 4.9
(IQR: 4.4–5.5)
5.0
(IQR: 4.5–5.9)
0.18 5.1
(IQR: 4.3–5.6)
5.0
(IQR: 4.5–5.7)
0.42
Median CD4+ T cells (cells/μl) 334
(IQR: 189–508)
374
(IQR: 232–566)
0.15 295
(IQR: 148–436)
383
(IQR: 238–540)
0.01
R infections based on testing history� and/or possible infection date 0 (0%) 6 (7%) NA 0 (0%) 7 (6%) NA
HCV serostatus��
Negative 54 (64%) 29 (46%) 0.03 34 (61%) 49 (54%) 0.49
Positive 30 (36%) 38 (54%) 22 (39%) 42 (46%)
HIV-1 subtype���
CRF06_cpx 61 (73%) 63 (93%) 0.003 35 (65%) 89 (92%) <0.001
Other 22 (27%) 5 (7%) 19 (35%) 8 (8%)
Significant differences are indicated in bold.
�Testing history; last negative HIV test was less than 130 days or less than 240 days prior to HIV diagnosis for LAg or BRAI, respectively.
��Persons with unknown HCV testing (n = 50) excluded
���Persons with unknown HIV subtype (n = 46) excluded; IQR, interquartile range; NA, not applicable.
https://doi.org/10.1371/journal.pone.0217048.t002
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In addition, our findings suggest that specimens with LAg-pending and BRAI-invalid test
results with both high CD4+ T cell counts and HIV-1 VLs may truly be recent infections.
These results may be specific to our study population and will require confirmation by testing
of additional CRFs and non-B subtypes from Estonia and elsewhere.
Our finding that BRAI classified more specimens as recent compared to LAg supports find-
ings from a previous report that observed longer BRAI MDRIs than those for LAg for HIV-1
subtypes A1, B, C and D [14]. Furthermore, in our analysis of MDRIs determined for subtype
B for both assays, the high concordance of both recent and long-term results for both LAg and
BRAI did not change when HIV-1 VL or AIDS diagnosis were taken into consideration to
decrease the false recency rate (FRR) [14]. These findings likely reflect differences in MDRIs
for each avidity assay that might not be the same as for subtype B. One can speculate that
Fig 4. Distribution of CD4+ T cell counts between persons classified as long-term (LT), pending/invalid and recent (R) in the LAg and BRAI assays (left
and right panels, respectively). The number of groups indicates the number of persons with CD4+ T cell count measurements within six months after HIV
diagnosis. Only significant differences are shown.
https://doi.org/10.1371/journal.pone.0217048.g004
Table 3. Distribution of subjects with a last negative HIV test prior to HIV diagnosis by LAg and BRAI testing.
LAg analysis groupa
Recent (n)/tested (n)
BRAI analysis groupa
Recent (n)/tested (n)
Persons with possible date of infection 4/4 (100%) 4/4 (100%)
Last negative HIV test prior to HIV diagnosis� 240 days 6/6b (100%) 6/6b (100%)
Last negative HIV test prior to HIV diagnosis� 2 years 16/19b (85%) 18/19b (95%)
aSubjects of the results of assays after inclusion of clinical data are presented.
bFour persons had possible date of infection available.
https://doi.org/10.1371/journal.pone.0217048.t003
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multiple freezing-thawing of samples might have impact on the results of the assays. However,
it has been previously shown that this does not influence the performance of the assays [20]. In
addition, samples tested by BRAI had only one extra freeze-thaw cycle than samples tested by
LAg, but not exceeding three cycles in total. Thus, freeze-thaw cycles were unlikely to have
influenced our results.
There are some possible limitations when comparing results from these two avidity assays,
including their inherently different MDRIs, which have been reported to be affected by HIV-1
subtype. For example, Duong et al (2015) showed that the LAg MDRI was 122 days for subtype
CRF01_AE, 152 days for subtypes C and BC and 109 days for subtypes A and D [16]. Further-
more, subtype D specimens were frequently misclassified by LAg and BRAI, likely due to weak
antibody responses to HIV in subtype D infected persons over time [12, 15, 21]. Variable
MDRI and FRRs among various HIV-1 subtypes (A1, B, C and D) was also reported by Kas-
sanjee et al. (2014) where MDRIs varied from 153 to 273 days for LAg and 298 for 467 days in
BRAI and the FRR ranged broadly from 0.5% to 9.1% and 2.1% to 54.5%, respectively [14].
Altogether, these reports demonstrate that avidity assay performance, characterized by MDRI
and FRR, for determining incidence can be affected by antibody response to different HIV-1
subtypes and also by the composition of subtype antigens present in the assay. As our study
population is predominantly infected with CRF06_cpx that do not contain subtype B-like
sequences [22, 23] in the gene regions of the HIV-1 proteins utilized in the avidity assays, it is
possible in our study that we may have misclassified some specimens using subtype B MDRIs.
Unfortunately, MDRIs for CRF06_cpx and subtype G (CRF06_cpx consists subtype G
sequence in env [23]) have not been estimated and would require specimen cohorts prior to
ART and seroconversion panels, which are not readily available. However, our results indicate
that MDRI is shorter in LAg than in BRAI.
Using high CD4+ T cell counts as a proxy for recently infected subjects, we observed higher
CD4+ T cell counts in recently infected subjects compared to those with established infection
by BRAI but not by LAg. Two scenarios may help explain these findings. First, the LAg assay
has a shorter MDRI and may have classified many specimens as recent, which were from per-
sons whose infections where in the phase where a transient increased drop in CD4+ T cell
counts occurs prior to reaching viral set-point. During this period CD4+ T cell counts are
sometimes similar between persons with recent and established infection. Alternatively, our
results may suggest that the longer MDRI of BRAI may be more suitable for distinguishing
recent and long-term infection in our study population. This possibility is supported by a
study by Hauser et al (2014) which reported that for subtype B virus infections BRAI per-
formed better than LAg with a true recency rate of 88% compared to 48% for LAg [12]. This
assay performance difference could also be explained by the use of only gp41 envelope epitopes
in LAg whereas multiple antigens are used in BRAI that can bind a broader spectrum of anti-
HIV-1 antibodies and therefore might perform differently. Interestingly, the median CD4+ T
cell count in persons determined to be recently infected by BRAI was relatively low (295 cells/
μL) contrasting with previous studies that showed the mean CD4+ T cell count in recently
infected subjects varied from 475 to 600 cells/μL [24]. Reasons for the lower CD4+ T cell
counts in recently infected Estonians in our study are not well understood but are consistent
with historical data in newly diagnosed patients in Estonia [25].
Only five subjects had known seroconversion dates and an additional two had negative
HIV antibody tests in the previous 240 days. Samples from these persons were used as refer-
ences for true recent infection and both avidity assays categorized all these subjects as recently
infected. In addition, 17 of 19 infected persons had negative HIV antibody/antigen combo
results during the last two years before testing positive and were also determined as recently
infected by both assays. These results suggest good performance of both avidity assays in
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detecting recent infections. We recognize that our findings are based on a small group of
patients, but recruitment of participants with known seroconversion dates is extremely diffi-
cult, especially in a population such as ours where the repeat testing rate is low (15%), likely
due to a relatively high rate of HIV-1-infected PWID [25].
Surprisingly, both assays initially categorized a relatively high number of samples as pend-
ing by LAg (18%) or invalid by BRAI (9%). It is important to note that all specimens in our
study were confirmed HIV-1-positive by WB or Ag testing and most of the persons also had
HIV-1 RNA detected by PCR. However, specific diagnostic results were not available to deter-
mine which specimens were HIV antigen reactive only and thus acute infections. All BRAI-
invalid samples were classified as recent infections, which is supported by the high HIV-1 VLs
and CD4+ T cell counts of these samples. Specimens with pending/invalid avidity test results
may also contain low or no antibody titers, since antibody reactivity was not detected in all of
the specimens. These results may also reflect HIV-1 subtype-dependent antibody responses as
suggested by Longosz et al (2014) who reported weaker avidity assay responses to HIV-1 sub-
type D [21]. Unfortunately, our study design did not permit any repeat specimen testing for
this purpose or for comparison of avidity results between different subtypes not present in
Estonia. Of note, we observed a lower rate of invalid samples in BRAI than pending samples in
the LAg assay, which may be due to the broader antigen composition of BRAI, including p24
antigens which are known to be one of the first anti-HIV antibody targets following infection.
In contrast, the LAg assay only contains a multi-subtype gp41 antigen. Thus, more detailed
studies to further evaluate the avidity of HIV-1 antibodies to subtype CRF06_cpx infection are
needed.
In summary, comparison of the LAg and BRAI avidity assays in this Estonian population
infected mainly by HIV-1 CRF06_cpx viruses showed good overall concordance (>90%) in
the categorization of the samples as recent or long-term infections. The different rates of recent
infection are likely explained by the different assay MDRIs. Additional studies with serocon-
version specimen panels from HIV-1-infected persons in Estonia are needed to further evalu-
ate the performance of avidity assays and to determine Estonian HIV-1 subtype-specific
MDRIs and FRRs.
Acknowledgments
We thank Bill Switzer for critical reading of the manuscript. Use of trade names is for identifi-
cation only and does not imply endorsement by the U.S. Department of Health and Human
Services, the Public Health Service, or the Centers for Disease Control and Prevention. The
findings and conclusions in this report are those of the authors and do not necessarily repre-
sent the views of the Centers for Disease Control and Prevention.
The full membership of CASCADE Collaboration in the EuroCoord:
CASCADE Steering Committee: Julia Del Amo (Chair), Laurence Meyer (Vice Chair), Hei-
ner C. Bucher, Geneviève Chêne, Osamah Hamouda, Deenan Pillay, Maria Prins, Magda
Rosinska, Caroline Sabin, Giota Touloumi.
CASCADE Co-ordinating Centre: Kholoud Porter (Project Leader), Ashley Olson, Andrea
Cartier, Lorraine Fradette, Sarah Walker, Abdel Babiker.
CASCADE Clinical Advisory Board: Heiner C. Bucher, Andrea De Luca, Martin Fisher,
Roberto Muga
CASCADE Collaborators: Australia PHAEDRA cohort (Tony Kelleher, David Cooper, Pat
Grey, Robert Finlayson, Mark Bloch) Sydney AIDS Prospective Study and Sydney Primary
HIV Infection cohort (Tony Kelleher, Tim Ramacciotti, Linda Gelgor, David Cooper, Don
Smith); Austria Austrian HIV Cohort Study (Robert Zangerle); Canada South Alberta clinic
Concordance of LAg and BRAI in an HIV-1 CRF06_cpx population
PLOS ONE | https://doi.org/10.1371/journal.pone.0217048 May 24, 2019 12 / 15
(John Gill); Estonia Tartu U¨likool (Irja Lutsar); France ANRS CO3 Aquitaine cohort (Gene-
viève Chêne, Francois Dabis, Rodolphe Thiebaut), ANRS CO4 French Hospital Database
(Dominique Costagliola, Marguerite Guiguet), Lyon Primary Infection cohort (Philippe Van-
hems), French ANRS CO6 PRIMO cohort (Marie-Laure Chaix, Jade Ghosn), ANRS CO2 SER-
OCO cohort (Laurence Meyer, Faroudy Boufassa); Germany German HIV-1 seroconverter
cohort (Osamah Hamouda, Karolin Meixenberger, Norbert Bannert, Barbara Bartmeyer);
Greece AMACS (Anastasia Antoniadou, Georgios Chrysos, Georgios L. Daikos); Greek Hae-
mophilia cohort (Giota Touloumi, Nikos Pantazis, Olga Katsarou); Italy Italian Seroconver-
sion Study (Giovanni Rezza, Maria Dorrucci), ICONA cohort (Antonella d’Arminio
Monforte, Andrea De Luca.) Netherlands Amsterdam Cohort Studies among homosexual
men and drug users (Maria Prins, Ronald Geskus, Jannie van der Helm, Hanneke Schuite-
maker); Norway, Oslo University Hospital cohorts (Mette Sannes, Anne Ma Dyrhol-Riise,
Anne-Marte Bakken Kran); Poland National Institute of Hygiene (Magdalena Rosinska);
Spain Badalona IDU hospital cohort (Roberto Muga, Jordi Tor), Barcelona IDU Cohort (Patri-
cia Garcia de Olalla, Joan Cayla), CoRIS-scv (Julia del Amo, Santiago Moreno, Susana
Monge); Madrid cohort (Julia Del Amo, Jorge del Romero), Valencia IDU cohort (Santiago
Pe´rez-Hoyos); Sweden Swedish InfCare HIV Cohort, Sweden (Anders So¨nnerborg); Switzer-
land Swiss HIV Cohort Study (Heiner C. Bucher, Huldrych Gu¨nthard, Alexandra Scherrer);
Ukraine Perinatal Prevention of AIDS Initiative (Ruslan Malyuta); United Kingdom Public
Health England (Gary Murphy), UK Register of HIV Seroconverters (Kholoud Porter, Anne
Johnson, Andrew Phillips, Abdel Babiker), University College London (Deenan Pillay); Afri-
can cohorts: Genital Shedding Study (US: Charles Morrison; Family Health International,
Robert Salata, Case Western Reserve University, Uganda: Roy Mugerwa, Makerere University,
Zimbabwe: Tsungai Chipato, University of Zimbabwe); International AIDS Vaccine Initiative
(IAVI) Early Infections Cohort (Kenya, Rwanda, South Africa, Uganda, Zambia: Matt A.
Price, IAVI, USA; Jill Gilmour, IAVI, UK; Anatoli Kamali, IAVI, Kenya; Etienne Karita, Projet
San Francisco, Rwanda).
EuroCoord Executive Board: Fiona Burns, University College London, UK; Geneviève
Chêne, University of Bordeaux, France; Dominique Costagliola (Scientific Coordinator), Insti-
tut National de la Sante´ et de la Recherche Me´dicale, France; Carlo Giaquinto, Fondazione
PENTA, Italy; Jesper Grarup, Region Hovedstaden, Denmark; Ole Kirk, Region Hovedstaden,
Denmark; Laurence Meyer, Institut National de la Sante´ et de la Recherche Me´dicale, France;
Heather Bailey, University College London, UK; Alain Volny Anne, European AIDS Treat-
ment Group, France; Alex Panteleev, St. Petersburg City AIDS Centre, Russian Federation;
Andrew Phillips, University College London, UK, Kholoud Porter, University College London,
UK; Claire Thorne, University College London, UK.
EuroCoord Council of Partners: Jean-Pierre Aboulker, Institut National de la Sante´ et de la
Recherche Me´dicale, France; Jan Albert, Karolinska Institute, Sweden; Silvia Asandi, Roma-
nian Angel Appeal Foundation, Romania; Geneviève Chêne, University of Bordeaux, France;
Dominique Costagliola (chair), INSERM, France; Antonella d’Arminio Monforte, ICoNA
Foundation, Italy; Ste´phane De Wit, St. Pierre University Hospital, Belgium; Peter Reiss,
Stichting HIV Monitoring, Netherlands; Julia Del Amo, Instituto de Salud Carlos III, Spain;
Jose´ Gatell, Fundacio´ Privada Clı´nic per a la Recerca Bı´omèdica, Spain; Carlo Giaquinto, Fon-
dazione PENTA, Italy; Osamah Hamouda, Robert Koch Institut, Germany; Igor Karpov, Uni-
versity of Minsk, Belarus; Bruno Ledergerber, University of Zurich, Switzerland; Jens
Lundgren, Region Hovedstaden, Denmark; Ruslan Malyuta, Perinatal Prevention of AIDS Ini-
tiative, Ukraine; Claus Møller, Cadpeople A/S, Denmark; Kholoud Porter, University College
London, United Kingdom; Maria Prins, Academic Medical Centre, Netherlands; Aza Rakhma-
nova, St. Petersburg City AIDS Centre, Russian Federation; Ju¨rgen Rockstroh, University of
Concordance of LAg and BRAI in an HIV-1 CRF06_cpx population
PLOS ONE | https://doi.org/10.1371/journal.pone.0217048 May 24, 2019 13 / 15
Bonn, Germany; Magda Rosinska, National Institute of Public Health, National Institute of
Hygiene, Poland; Manjinder Sandhu, Genome Research Limited; Claire Thorne, University
College London, UK; Giota Touloumi, National and Kapodistrian University of Athens,
Greece; Alain Volny Anne, European AIDS Treatment Group, France.
EuroCoord External Advisory Board: David Cooper, University of New South Wales, Aus-
tralia; Nikos Dedes, Positive Voice, Greece; Kevin Fenton, Public Health England, USA; David
Pizzuti, Gilead Sciences, USA; Marco Vitoria, World Health Organisation, Switzerland.
EuroCoord Secretariat: Silvia Faggion, Fondazione PENTA, Italy; Lorraine Fradette, Uni-
versity College London, UK; Richard Frost, University College London, UK; Andrea Cartier,
University College London, UK; Dorthe Raben, Region Hovedstaden, Denmark; Christine
Schwimmer, University of Bordeaux, France; Martin Scott, UCL European Research & Inno-
vation Office, UK.
Author Contributions
Conceptualization: Kristi Huik, Irja Lutsar.
Data curation: Kristi Huik, Pilleriin Soodla, Heli Rajasaar.
Formal analysis: Kristi Huik.
Funding acquisition: Irja Lutsar.
Investigation: Kristi Huik, Pilleriin Soodla, Merit Pauskar, S. Michele Owen, Ene-Ly Jõgeda,
Eveli Kallas, Radko Avi, Silvina Masciotra, Irja Lutsar.
Methodology: Kristi Huik, Pilleriin Soodla, Merit Pauskar, S. Michele Owen, Wei Luo, Gary
Murphy, Ene-Ly Jõgeda, Eveli Kallas, Radko Avi, Silvina Masciotra.
Supervision: Irja Lutsar.
Writing – original draft: Kristi Huik.
Writing – review & editing: S. Michele Owen, Silvina Masciotra, Irja Lutsar.
References
1. Adojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K, et al. Predominance of a rare type of
HIV-1 in Estonia. J Acquir Immune Defic Syndr. 2005; 39(5):598–605. PMID: 16044014.
2. Avi R, Huik K, Sadam M, Karki T, Krispin T, Ainsalu K, et al. Absence of genotypic drug resistance and
presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06_cpx
in treatment-naive patients in Estonia. J Med Virol. 2009; 81(6):953–8. https://doi.org/10.1002/jmv.
21482 PMID: 19382254.
3. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, et al. Performance characteris-
tics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J
Acquir Immune Defic Syndr. 2003; 33(5):625–34. PMID: 12902808.
4. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, et al. Development of a new
less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic
Syndr. 2003; 33(3):349–55. PMID: 12843746.
5. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, Parry JV, et al. Human immunodeficiency
virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-
seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol. 2007; 45(2):415–20.
https://doi.org/10.1128/JCM.01879-06 PMID: 17151211.
6. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, et al. Detection of recent HIV-1 infection using
a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation stud-
ies. PLoS One. 2012; 7(3):e33328. https://doi.org/10.1371/journal.pone.0033328 PMID: 22479384.
7. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, et al. Quantitative detection of increas-
ing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and
Concordance of LAg and BRAI in an HIV-1 CRF06_cpx population
PLOS ONE | https://doi.org/10.1371/journal.pone.0217048 May 24, 2019 14 / 15
estimating incidence. AIDS Res Hum Retroviruses. 2002; 18(4):295–307. https://doi.org/10.1089/
088922202753472874 PMID: 11860677.
8. Curtis KA, Kennedy MS, Charurat M, Nasidi A, Delaney K, Spira TJ, et al. Development and characteri-
zation of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum
Retroviruses. 2012; 28(2):188–97. https://doi.org/10.1089/AID.2011.0037 PMID: 21585287.
9. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, et al. HIV incidence
determination in the United States: a multiassay approach. The Journal of infectious diseases. 2013;
207(2):232–9. https://doi.org/10.1093/infdis/jis659 PMID: 23129760; PubMed Central PMCID:
PMCPMC3532826.
10. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, et al. Development of two avidity-based assays
to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res
Hum Retroviruses. 2010; 26(1):61–71. https://doi.org/10.1089/aid.2009.0133 PMID: 20063992.
11. CEPHIA Project Team. Evaluation of Bio-Rad GS HIV-1/HIV-2 PLUS O EIA Avidity Assay.
12. Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, et al. Improved
testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity
assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the
German Seroconverter Cohort. PloS one. 2014; 9(6):e98038. https://doi.org/10.1371/journal.pone.
0098038 PMID: 24892795; PubMed Central PMCID: PMCPMC4043688.
13. Curtis KA, Price KA, Niedzwiedz P, Masciotra S, Owen M. Short Communication: Persistence of HIV
Antibody Avidity in the Presence of Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2016; 32
(6):561–3. https://doi.org/10.1089/AID.2015.0247 PMID: 26887862.
14. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assess-
ment of candidate HIV incidence assays on specimens in the CEPHIA repository. Aids. 2014; 28
(16):2439–49. https://doi.org/10.1097/QAD.0000000000000429 PMID: 25144218.
15. Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, et al. Incorrect identification of
recent HIV infection in adults in the United States using a limiting-antigen avidity assay. Aids. 2014; 28
(8):1227–32. https://doi.org/10.1097/QAD.0000000000000221 PMID: 24513567; PubMed Central
PMCID: PMCPMC4102639.
16. Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen
avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One.
2015; 10(2):e0114947. https://doi.org/10.1371/journal.pone.0114947 PMID: 25710171.
17. Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, et al. Comparison of antibody
responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Ret-
roviruses. 2015; 31(4):421–7. https://doi.org/10.1089/AID.2014.0081 PMID: 25317854.
18. Hanson DL, Song R, Masciotra S, Hernandez A, Dobbs TL, Parekh BS, et al. Mean Recency Period for
Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in
the United States with Subtype B. PLoS One. 2016; 11(4):e0152327. https://doi.org/10.1371/journal.
pone.0152327 PMID: 27065005.
19. Soodla P, Rajasaar H, Avi R, Zilmer K, Kink K, Novikova L, et al. Design and structure of the Estonian
HIV Cohort Study (E-HIV). Infect Dis (Lond). 2015; 47(11):768–75. https://doi.org/10.3109/23744235.
2015.1061203 PMID: 26153824.
20. Laeyendecker O, Latimore A, Eshleman SH, Summerton J, Oliver AE, Gamiel J, et al. The effect of
sample handling on cross sectional HIV incidence testing results. PLoS One. 2011; 6(10): e25899.
https://doi.org/10.1371/journal.pone.0025899 PMID: 22046249
21. Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, et al. Impact of HIV subtype on
performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the
BED capture immunoassay in Rakai, Uganda. AIDS Res Hum Retroviruses. 2014; 30(4):339–44.
https://doi.org/10.1089/AID.2013.0169 PMID: 24083837; PubMed Central PMCID: PMCPMC3976571.
22. Avi R, Huik K, Pauskar M, Ustina V, Karki T, Kallas E, et al. Transmitted drug resistance is still low in newly
diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. AIDS
Res Hum Retroviruses. 2014; 30(3):278–83. https://doi.org/10.1089/AID.2012.0357 PMID: 24025024.
23. www.hiv.lanl.gov
24. Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, et al. Rate of CD4 decline and HIV-RNA change fol-
lowing HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO
and CASCADE cohorts. J Acquir Immune Defic Syndr. 2013; 62(4):441–6. https://doi.org/10.1097/QAI.
0b013e31827f5c9a PMID: 23221982.
25. Soodla, Simmons R, Huik K, Pauskar M, Jõgeda EL, Rajasaar H, et al. HIV incidence in the Estonian
population in 2013 using the HIV-1 Limiting Antigen Avidity (LAg) assay. HIV Medicine. 2017.
Concordance of LAg and BRAI in an HIV-1 CRF06_cpx population
PLOS ONE | https://doi.org/10.1371/journal.pone.0217048 May 24, 2019 15 / 15
